Fund Manager Summary on Polynovo Ltd (ASX:PNV)
In January 2026, Forager Funds commented that Polynovo Ltd (ASX:PNV)'s NovoSorb product is applicable across many wound types but is not suitable for necrotized wounds, where competitor Aroa's product is preferred. Overall, fund manager commentary on Polynovo (ASX:PNV) balances a view of strong underlying growth and a material valuation gap with caution on clinical differentiation and addressable-market limits: Endeavor Asset Management re-entered the stock in April 2025 after a significant derating despite little change to fundamentals, highlighting NovoSorb BTM as the flagship, noting a historical three-year average forward EV/Sales of 12x versus about 5x at the time and consensus forecasts of revenue and EBITDA CAGRs of 21% and 62% to FY29e, and reporting re-entry at $1.05 after an earlier exit at $1.82 when the share price was ~1.21, while Forager emphasized that NovoSorb cannot be used for necrotized wounds and that different products serve different clinical needs; actionable considerations include tracking clinical evidence and indication expansion for necrotic wounds, monitoring competitive dynamics with Aroa and similar rivals, assessing execution against the consensus revenue and margin assumptions that justify a valuation re-rating, and watching for corporate or commercial catalysts, with primary risks being product limitations by wound type, competitive displacement and adoption or execution shortfalls.
Commentary From The Managers
There are 12 insights from 4 fund managers regarding their investment in Polynovo Ltd (ASX:PNV) available on Thesis Tracker.
Unlock Updates With ThesisTracker Pro
Don’t let information asymmetry undermine your investment returns. Join other engaged investors on ThesisTracker Pro.
Updates are made available to members within 12 hours of being released. The completeness, accuracy or current status of the investments referenced are not guaranteed.
Commentary From The Managers
Forager Funds
22 Jan 2026
$1.12
Summary
- Forager Funds believes Polynovo’s Nova product is a versatile, differentiated wound‑care technology and continues to hold because it addresses a wide set of non‑necrotic wound indications, occupies a clear clinical niche versus direct competitors, and provides long‑term optionality from multiple use cases.
- Product scope: Nova can be used for many different wound types, offering utility across acute and chronic wounds, but it is not suitable for necrotized wounds.
- Competitive positioning: Aroa’s product is effectively the primary option for necrotized wounds, so Polynovo and Aroa are complementary in clinical practice rather than direct substitutes for every indication.
- Clinical adoption implications: clinicians will choose products by wound type — Nova for a broad set of non‑necrotic wounds and Aroa where necrotic tissue management is required — which supports differentiated market niches.
- Market opportunity and optionality: the breadth of use cases for Nova creates multiple commercial pathways (hospital, outpatient, specialty care), increasing the company’s upside if uptake grows.
- Key risks: clear segmentation by wound type (e.g., necrotic vs non‑necrotic) means adoption depends on educating clinicians about where Nova fits versus competing therapies; execution, reimbursement and regulatory factors remain material.
- Net view: the combination of a versatile product, a definable clinical niche, and a complementary competitive landscape underpins the decision to hold exposure to Polynovo.
Endeavor Asset Management
30 Apr 2025
$1.21
Summary
- Endeavor Asset Management re-entered Polynovo (PNV) in April after a significant decline in share price.
- The share price drop occurred despite minimal changes in the company's underlying fundamentals.
- Polynovo’s flagship product, NovoSorb BTM, is a synthetic dermal matrix that aids skin regeneration.
- The stock has historically traded at an average forward EV/Sales multiple of 12x, significantly higher than the current multiple of 5x.
- Consensus forecasts indicate strong growth, with revenues and EBITDA expected to compound at 21% and 62% per annum, respectively, through FY29e.
- Endeavor Asset Management previously exited their position at $1.82 per share but reinitiated at $1.05.
Selector Funds Management
31 Dec 2024
$2.04
Summary
- PolyNovo announced record monthly sales of $10.1m for November.
- The U.S. business delivered sales of $7m.
- Total revenue for the financial year to date is $49.6m, up 25% on the prior corresponding period.
- CEO Swami Raote expressed gratitude to clinicians and partners for embracing NovoSorb.
- NovoSorb is gaining traction as a preferred platform for soft tissue reconstruction.
- NovoSorb MTX, the new monolayer product, is on a steep adoption curve in the U.S.
- Patient impact has expanded to over 62,000 globally, outpacing revenue growth.
- PolyNovo has a market capitalisation of $1.3b.
Endeavor Asset Management
31 Aug 2024
$2.35
Summary
- Endeavor Asset Management notes a 31% rise in Polynovo shares over the three months to July.
- In August, shares declined 13%, but the company confirmed strong FY24 revenue performance.
- The outlook indicates continued business growth.
- Management reported early success with product price increases.
- Positive progress is evident across the company’s broad product pipeline.
- With competitor Integra temporarily out of the market, FY25 is expected to be another strong year for Polynovo.
- Endeavor Asset Management continues to hold due to these positive indicators.
Blackwattle Investment Partners
31 Aug 2024
$2.35
Summary
- Polynovo fell 13% in August after delivering an inline result.
- The reason for the share price drop is unclear, as FY25 is shaping up as a good year for the company.
- PNV’s Barda trial has completed recruitment and data release is expected shortly.
- Anticipated results are expected to drive further adoption in the core US market.
- Competitor Integra continues to face challenges due to product recalls.
- Integra’s products are only now being depleted from inventories, positioning PNV to benefit significantly.
- Blackwattle Investment Partners continues to hold because of these positive developments.
Endeavor Asset Management
31 July 2024
$2.68
Summary
- Endeavor Asset Management notes that Wound care company Polynovo (PNV) lifted 9.4% in July following a preliminary earnings release for FY24.
- Revenue of $104.8 million was 2% ahead of consensus and increased by 58% year-over-year.
- US sales grew by 49% while sales in the rest of the world increased by 73%, highlighting successful global expansion.
- The company’s Novosorb burns product is considered best in class.
- Endeavor Asset Management expects FY25 to show continued sales growth and profitability.
Endeavor Asset Management
30 June 2024
$2.33
Summary
- Endeavor Asset Management notes a 9% increase in PolyNovo's share price in June.
- Observed a strong performance leading up to the end of the financial year.
- Highlighting that a 7% sell-off was deemed overdone by the fund manager.
- Noted an eventual recovery of over 10% in share price.
- Positive broker research continues to support the investment case.
- Endeavor Asset Management maintains its position in PolyNovo.
Endeavor Asset Management
31 May 2024
$2.25
Summary
- Endeavor Asset Management notes a 9.8% share price increase for PolyNovo (PNV) in May, driven by strong demand.
- The company reported a record group revenue of A$10.1 million in April.
- Projections indicate commercial revenues may reach A$53 million in the second half of 2024.
- Novosorb BTM is expected to become the standard of care for burns and trauma in the US market.
- Significant revenue growth outside the US has been observed, particularly in UK/Ireland, ANZ, HK, and Germany.
- Endeavor Asset Management participated in a visit to PolyNovo's Port Melbourne facility, reinforcing their investment thesis.
Endeavor Asset Management
31 Mar 2024
$2.14
Summary
- Endeavor Asset Management continues to hold an investment in Polynovo Ltd.
- Despite a positive earnings report in late February, the company experienced a 4% decline in share price in March.
- This decline is attributed to consolidation following a significant rally.
- The stock performance was a detractor to overall performance.
- Polynovo's fundamentals remain strong, supported by broad adoption of its core product.
- Ongoing regulatory progress continues to bolster its long-term growth potential.
Selector Funds Management
31 Mar 2024
$2.14
Summary
- PolyNovo is a medical device business specializing in synthetic bioabsorbable polymer solutions.
- Leading product Novosorb BTM was approved in the U.S. in 2015 and in Europe in 2019.
- The company employs 237 staff globally and has treated over 37,000 patients in 37 countries.
- In the first half of financial year 2024, PolyNovo posted its first period of profitability and expects to remain profitable throughout the year.
- Growth was driven by educational awareness activities and sales efforts to increase product adoption across hospitals.
- Hospital accounts increased 67% to 861, with 154 new customers added in the U.S., totaling over 410 hospitals.
- Growth is attributed to direct sales efforts and network effects from physicians introducing the company to new departments and locations.
- Physician publications of Novosorb BTM increased from 214 to over 230 in the half.
- Management credits the growing clinical interest to Novosorb BTM's versatility in delivering differentiated patient outcomes.
- Revenue and profit growth are evident, with manufactured units increasing from 17,000 in FY 2022 to approximately 49,000 in the first half of FY 2024.
- International revenue outside the U.S. more than doubled to $10m, led by growth in the UK and Germany.
- PolyNovo claims to be the market leader in advanced dermal substitute procedures in the UK and Germany, and for burns in ANZ.
- The company is building its team in India, with 16 sales representatives, focusing on winning government tenders.
- PolyNovo has won a government veteran tender and was included on the Indian Government-e-Marketplace (GeM) portal.
- Anticipates its first order through the GeM platform within a month.
- Continues to invest in people, product, and infrastructure to scale the business.
- Aims to start development of a third manufacturing plant in Port Melbourne in Q1 2025, costing circa $25m.
- The new facility is designed for product flexibility and higher output, supporting ambitions for a larger product portfolio.
- Management expects the facility to support circa $500m in sales.
- PolyNovo has a market capitalization of $1.5b.
Endeavor Asset Management
28 Feb 2024
$2.13
Summary
- Endeavor Asset Management continues to hold shares in Polynovo Ltd. (PNV) following a 20% increase in shares over the month.
- The first-half results showcased strong sales growth of 60% compared to the previous corresponding period (pcp).
- Polynovo has entered positive Net Profit After Tax (NPAT) territory.
- Sales growth has surpassed market expectations in both the US and the Rest of World (RoW), with RoW contributing 25% of first half sales.
- PNV’s dominant market position and global sales traction are notable.
- The company’s well-controlled costs support a view that shares should trade at a material premium to peers.
Endeavor Asset Management
31 Jan 2024
$1.91
Summary
- Polynovo was the second largest contributor after announcing sales ahead of expectations.
- Total sales grew 66% year on year, with 122% growth outside of the US.
- Achieved profitability during the half.
- Several near-term positive catalysts identified.
- Significant longer-term opportunities in additional indications.
- Endeavor Asset Management continues to hold due to these factors.
The completeness, accuracy or current status of the investments referenced are not guaranteed.
Frequently Asked Questions
Who is investing in Polynovo Ltd (ASX:PNV)?
Fund managers including Endeavor Asset Management, Blackwattle Investment Partners, Selector Funds Management and Forager Funds have invested in Polynovo Ltd (ASX:PNV).
Why do fund managers invest in Polynovo Ltd?
Fund managers invest in Polynovo Ltd due to its potential for significant growth and strong market fundamentals. The company's flagship product, NovoSorb BTM, supports skin regeneration and is well-positioned in the wound care sector. Despite a recent drop in share price, its current valuation is significantly lower than historical averages, presenting a compelling opportunity. Analysts forecast robust revenue and EBITDA growth, estimated at 21% and 62% annually through FY29, enhancing its attractiveness as a long-term investment.
What happened to Polynovo Ltd (ASX:PNV)?
There have been no recent updates from fund managers regarding Polynovo Ltd although fund managers including Endeavor Asset Management, Blackwattle Investment Partners and Selector Funds Management have previously commented.
What is the short interest in Polynovo Ltd (ASX:PNV)?
The short interest in Polynovo Ltd (ASX:PNV) is 11.35% which makes it the seventh most shorted stock on the ASX. Of the 690.8M shares that Polynovo Ltd has on issue, 78.4M have been sold short.
What does Polynovo Ltd (ASX:PNV) do?
Polynovo Ltd. engages in the development of medical devices, utilizing the patented polymer technology NovoSorb. It focuses on biodegradable temporizing matrix (BTM) product. It operates through the United States of America, Australia and New Zealand, and Other Countries geographical segments. The company was founded on August 12, 1998 and is headquartered in Port Melbourne, Australia.